Proposed Data Collection Submitted for Public Comment and Recommendations, 18630-18631 [2016-07226]
Download as PDF
<![CDATA[
18630
Federal Register / Vol. 81, No. 62 / Thursday, March 31, 2016 / Notices
Dated: March 24, 2016.
John Hofmann,
Division Director, Facilities Management &
Services Programs Division, General Services
Administration, Mid-Atlantic Region.
[FR Doc. 2016–07161 Filed 3–30–16; 8:45 am]
BILLING CODE 6820–89–P
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment should be
submitted through the Federal eRulemaking
portal (Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day–16–16XD; Docket No. CDC–2016–
0034]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a newly proposed
information collection project entitled
‘‘Practice Patterns Related to Opioid Use
During Pregnancy and Lactation’’. CDC
seeks to collect data for the purpose of
assessing obstetrician-gynecologists’
knowledge, attitudes, and practices
regarding screening for and treatment of
maternal opioid use surrounding the
time of pregnancy. CDC will need a oneyear clearance from the Office of
Management and Budget (OMB) to
collect the necessary data.
DATES: Written comments must be
received on or before May 31, 2016.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2016–
0034 by any of the following methods:
Federal eRulemaking Portal:
Regulation.gov. Follow the instructions
for submitting comments.
Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS–
D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:09 Mar 30, 2016
Jkt 238001
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS–D74, Atlanta,
Georgia 30329; phone: 404–639–7570;
Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
maintaining information, and disclosing
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
Proposed Project
Practice Patterns Related to Opioid
Use During Pregnancy and Lactation—
New—National Center for Chronic
Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Over the past decade, the prevalence
of maternal opioid use during
pregnancy has steadily increased. The
use of opioids or other psychoactive
substances, either by illicit abuse or by
nonmedical abuse of prescription
opioids, increases the risks for health
and social problems for both mother and
infant. For example, maternal substance
abuse during pregnancy increases the
risk of preterm birth, low birth weight,
perinatal death, and neonatal abstinence
syndrome (NAS). For many women, and
some at-risk women in particular,
prenatal visits may be the only time
they routinely see a physician. Because
obstetrician-gynecologists (OB/GYNs)
are the principal health care providers
for women, OB/GYNs are well situated
to screen for substance use and to treat
or encourage cessation of substance use
during pregnancy. Thus, it is important
to understand current provider
knowledge, attitudes, and practices
regarding maternal opioid use.
CDC, in collaboration with the
American College of Obstetricians and
Gynecologists (ACOG), plans to conduct
a survey to address this gap in
knowledge. Survey respondents will be
ACOG Fellows and Junior Fellows who
have a current medical license and are
in medical practice focused on women’s
health. ACOG is separated into 11
districts, one of which represents OB/
GYN members who are in the U.S.
military. The remaining 10 ACOG
districts correspond to geographic
regions that encompass the entire
United States and Canada. Survey
invitations will be sent to a quasirandom sample of ACOG members in
each district.
CDC and ACOG estimate that 1,500
individuals will be contacted in order to
obtain a study target of 600 respondents.
The initial invitation will be distributed
by email with instructions on
completing a web-based version of the
questionnaire. Three to four months
after the initial invitation, a paper
version of the questionnaire will be
E:\FR\FM\31MRN1.SGM
31MRN1
18631
Federal Register / Vol. 81, No. 62 / Thursday, March 31, 2016 / Notices
distributed to individuals who have not
completed the online version. The
estimated number of respondents for the
full web-based or paper questionnaire is
420 and the estimated burden per
response is 15 minutes. Approximately
six weeks after the second recruitment
attempt, ACOG will distribute a short
version of the questionnaire to any nonresponders. The estimated number of
responses for the short version of the
questionnaire is 180 and the estimated
No information will be collected
about individual patients. Survey
administration and data management
will be conducted by ACOG, and
participation is voluntary. De-identified
response data will be shared with CDC
for analysis.
Findings will be used to create
recommendations for educational
programs and patient care. There are no
costs to participants other than their
time.
burden per response is 5 minutes. An
overall 40% response rate is expected.
The survey will collect information
about provider attitudes and beliefs
regarding maternal opioid use, their
screening and referral practices for
pregnant or postpartum patients,
barriers to screening and treating
pregnant and postpartum patients for
opioid use, and resources that are
needed to improve treatment and
referral.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
OB/GYNs caring for
pregnant women.
Total ........................
Practice Patterns
Pregnancy and
Practice Patterns
Pregnancy and
420
1
15/60
105
180
1
5/60
15
..............................................................................
........................
........................
........................
120
[FR Doc. 2016–07226 Filed 3–30–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–16–1074]
Agency Forms Undergoing Paperwork
Reduction Act Review
mstockstill on DSK4VPTVN1PROD with NOTICES
Total burden
(in hours)
Related to Opioid Use During
Lactation.
Related to Opioid Use During
Lactation (short version).
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
VerDate Sep<11>2014
Average
burden per
response
(in hours)
Number of
responses per
respondent
Number of
respondents
Form name
19:09 Mar 30, 2016
Jkt 238001
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
Colorectal Cancer Control Program
(CRCCP) Monitoring Activities
—Reinstatement with Change (OMB No.
0920–1074, exp. 12/31/2015)
—National Center for Chronic Disease
Prevention and Health Promotion
(NCCDPHP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
CDC is requesting a reinstatement
with change of the information collect
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
project assigned OMB Control Number
0920–1074, formerly entitled ‘‘Annual
Survey of Colorectal Cancer Control
Activities Conducted by States and
Tribal Organizations.’’ In the previous
OMB approval period, information
collection consisted of an annual
grantee survey. In the next OMB
approval period, information collection
will consist of a redesigned survey and
a new clinic-level information
collection. The number of respondents
will increase and the total estimated
annualized burden will increase.
Among cancers that affect both men
and women, colorectal cancer (CRC) is
the second leading cause of death from
cancer in the United States. CRC
screening has been shown to reduce
incidence of and death from the disease.
Screening for CRC can detect disease
early when treatment is more effective
and prevent cancer by finding and
removing precancerous polyps. Of
individuals diagnosed with early stage
CRC, more than 90% live five or more
years. Despite strong evidence
supporting screening, only 65% of
adults currently report being up-to-date
with CRC screening as recommended by
the U.S. Preventive Services Task Force,
with more than 22 million age-eligible
adults estimated to be untested. To
reduce CRC morbidity, mortality, and
associated costs, use of CRC screening
tests must be increased among ageeligible adults with the lowest CRC
screening rates.
CDC’s Colorectal Cancer Control
Program (CRCCP) currently provides
funding to 31 grantees under
‘‘Organized Approaches to Increase
E:\FR\FM\31MRN1.SGM
31MRN1
]]>Agencies
[Federal Register Volume 81, Number 62 (Thursday, March 31, 2016)]
[Notices]
[Pages 18630-18631]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-07226]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60 Day-16-16XD; Docket No. CDC-2016-0034]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing efforts to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies to take this opportunity to comment on proposed and/or
continuing information collections, as required by the Paperwork
Reduction Act of 1995. This notice invites comment on a newly proposed
information collection project entitled ``Practice Patterns Related to
Opioid Use During Pregnancy and Lactation''. CDC seeks to collect data
for the purpose of assessing obstetrician-gynecologists' knowledge,
attitudes, and practices regarding screening for and treatment of
maternal opioid use surrounding the time of pregnancy. CDC will need a
one-year clearance from the Office of Management and Budget (OMB) to
collect the necessary data.
DATES: Written comments must be received on or before May 31, 2016.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2016-
0034 by any of the following methods:
Federal eRulemaking Portal: Regulation.gov. Follow the instructions
for submitting comments.
Mail: Leroy A. Richardson, Information Collection Review Office,
Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS-
D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. All relevant comments received will be posted
without change to Regulations.gov, including any personal information
provided. For access to the docket to read background documents or
comments received, go to Regulations.gov.
Please note: All public comment should be submitted through the
Federal eRulemaking portal (Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact the Information Collection Review Office,
Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS-
D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; (d) ways to
minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology; and (e) estimates of capital or start-
up costs and costs of operation, maintenance, and purchase of services
to provide information. Burden means the total time, effort, or
financial resources expended by persons to generate, maintain, retain,
disclose or provide information to or for a Federal agency. This
includes the time needed to review instructions; to develop, acquire,
install and utilize technology and systems for the purpose of
collecting, validating and verifying information, processing and
maintaining information, and disclosing and providing information; to
train personnel and to be able to respond to a collection of
information, to search data sources, to complete and review the
collection of information; and to transmit or otherwise disclose the
information.
Proposed Project
Practice Patterns Related to Opioid Use During Pregnancy and
Lactation--New--National Center for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
Over the past decade, the prevalence of maternal opioid use during
pregnancy has steadily increased. The use of opioids or other
psychoactive substances, either by illicit abuse or by nonmedical abuse
of prescription opioids, increases the risks for health and social
problems for both mother and infant. For example, maternal substance
abuse during pregnancy increases the risk of preterm birth, low birth
weight, perinatal death, and neonatal abstinence syndrome (NAS). For
many women, and some at-risk women in particular, prenatal visits may
be the only time they routinely see a physician. Because obstetrician-
gynecologists (OB/GYNs) are the principal health care providers for
women, OB/GYNs are well situated to screen for substance use and to
treat or encourage cessation of substance use during pregnancy. Thus,
it is important to understand current provider knowledge, attitudes,
and practices regarding maternal opioid use.
CDC, in collaboration with the American College of Obstetricians
and Gynecologists (ACOG), plans to conduct a survey to address this gap
in knowledge. Survey respondents will be ACOG Fellows and Junior
Fellows who have a current medical license and are in medical practice
focused on women's health. ACOG is separated into 11 districts, one of
which represents OB/GYN members who are in the U.S. military. The
remaining 10 ACOG districts correspond to geographic regions that
encompass the entire United States and Canada. Survey invitations will
be sent to a quasi-random sample of ACOG members in each district.
CDC and ACOG estimate that 1,500 individuals will be contacted in
order to obtain a study target of 600 respondents. The initial
invitation will be distributed by email with instructions on completing
a web-based version of the questionnaire. Three to four months after
the initial invitation, a paper version of the questionnaire will be
[[Page 18631]]
distributed to individuals who have not completed the online version.
The estimated number of respondents for the full web-based or paper
questionnaire is 420 and the estimated burden per response is 15
minutes. Approximately six weeks after the second recruitment attempt,
ACOG will distribute a short version of the questionnaire to any non-
responders. The estimated number of responses for the short version of
the questionnaire is 180 and the estimated burden per response is 5
minutes. An overall 40% response rate is expected.
The survey will collect information about provider attitudes and
beliefs regarding maternal opioid use, their screening and referral
practices for pregnant or postpartum patients, barriers to screening
and treating pregnant and postpartum patients for opioid use, and
resources that are needed to improve treatment and referral.
No information will be collected about individual patients. Survey
administration and data management will be conducted by ACOG, and
participation is voluntary. De-identified response data will be shared
with CDC for analysis.
Findings will be used to create recommendations for educational
programs and patient care. There are no costs to participants other
than their time.
Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondents Form name respondents responses per response (in (in hours)
respondent hours)
--------------------------------------------------------------------------------------------------------------------------------------------------------
OB/GYNs caring for pregnant women.............. Practice Patterns Related to Opioid Use 420 1 15/60 105
During Pregnancy and Lactation.
Practice Patterns Related to Opioid Use 180 1 5/60 15
During Pregnancy and Lactation (short
version).
---------------------------------------------------------------
Total...................................... ....................................... .............. .............. .............. 120
--------------------------------------------------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2016-07226 Filed 3-30-16; 8:45 am]
BILLING CODE 4163-18-P
